DK2425824T3 - Farmaceutisk præparat indeholdende oxycodon og naloxon - Google Patents

Farmaceutisk præparat indeholdende oxycodon og naloxon Download PDF

Info

Publication number
DK2425824T3
DK2425824T3 DK11177516.9T DK11177516T DK2425824T3 DK 2425824 T3 DK2425824 T3 DK 2425824T3 DK 11177516 T DK11177516 T DK 11177516T DK 2425824 T3 DK2425824 T3 DK 2425824T3
Authority
DK
Denmark
Prior art keywords
receiver
communication module
conductive
module
signal
Prior art date
Application number
DK11177516.9T
Other languages
English (en)
Other versions
DK2425824T5 (da
Inventor
Bianca BRÖGMANN
Silke MÜHLAU
Christof Spitzley
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28676052&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2425824(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE10215131A external-priority patent/DE10215131A1/de
Priority claimed from DE10215067A external-priority patent/DE10215067A1/de
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Application granted granted Critical
Publication of DK2425824T3 publication Critical patent/DK2425824T3/da
Publication of DK2425824T5 publication Critical patent/DK2425824T5/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Claims (10)

1. En enhed (102) omfattende: en spiselig komponent omfattende et integreret kredsløb (206) omfattende et første ledende kommunikationsmodul konfigureret til at generere og sende et første signal, hvor det første signal er et ledende nærfeltssignal, som kommunikeres via en ledende kommunikationsprotokol, som bruger kropsvæske som et ledende medium; og et andet ikke-ledende kommunikationsmodul konfigureret til at generere og sende et andet signal, hvor det andet signal kommunikeres via en ikke-ledende kommunikationsprotokol; hvor det første ledende kommunikationsmodul separeres fra det andet ikke-ledende kommunikationsmodul.
2. Enheden ifølge krav 1, hvor det andet ikke-ledende kommunikationsmodul omfatter mindst et modul udvalgt blandt gruppen bestående af et trådløst radiofrekvensmodul, et magnetisk induktionsmodul, et optisk modul, et akustisk modul og et kabelforbundet modul, helst hvor det trådløse radiofrekvensmodul omfatter et radiofrekvensidentifikationsmodul, eller hvor det optiske modul omfatter et infrarødt frekvensmodul.
3. Enheden ifølge krav 1 eller 2, hvor den spiselige komponent omfatter en strømkilde, helst hvor strømkilden omfatter et par elektroder (22, 24) fremstillet af forskellige materialer, eller hvor enheden omfatter en anden strømkilde elektrisk koblet til det ikke-ledende kommunikationsmodul, helst hvor den anden strømkilde omfatter en spole.
4. Enheden ifølge ethvert af foregående krav, hvor den spiselige komponent omfatter det ikke-ledende kommunikationsmodul, helst hvor det ikke-ledende kommunikationsmodul er elektrisk koblet til den spiselige komponents integrerede kredsløb, hvor den spiselige komponents integrerede kredsløb, det ledende kommunikationsmodul og mindst en del af det ikke-ledende kommunikationsmodul er integreret i en identifikationskomponent, eller hvor det ikke-ledende kommunikationsmodul omfatter en ikke-ledende sender, helst hvor den ikke-ledende sender er associeret med den spiselige komponent, eller hvor den ikke-ledende sender er associeret med en emballagekomponent til enheden.
5. Enheden ifølge ethvert af foregående krav, hvor det ikke-ledende kommunikationsmodul er elektrisk koblet til et andet integreret kredsløb, som er særskilt fra den spiselige komponents integrerede kredsløb, helst hvor det andet integrerede kredsløb og den spiselige komponents integrerede kredsløb er konfigureret til at kommunikere med hinanden, eller hvor mindst en del af det ikke-ledende kommunikationsmodul er konfigureret til at blive separeret fra den spiselige komponent på en måde, som ikke omfatter det ledende kommunikationsmoduls funktion, eller hvor den spiselige komponent omfatter et aktivt, farmaceutisk middel, eller hvor den spiselige komponent omfatter et fysiologisk acceptabelt transportmiddel, helst hvor det fysiologisk acceptable transportmiddel er konfigureret som en tablet eller kapsel.
6. Et system omfattende: en enhed (102) ifølge ethvert af foregående krav og en modtager (106); hvor modtageren (106), det første ledende kommunikationsmodul og det andet ikke-ledende kommunikationsmodul er konfigureret til at overføre informationer mellem modtageren og mindst en af det første ledende kommunikationsmodul eller det andet ikke-ledende kommunikationsmodul.
7. Systemet ifølge krav 6, hvor modtageren (106) er konfigureret til at modtage mindst en af det første signal eller det andet signal, helst hvor modtageren (106) er konfigureret til at modtage det andet signal, helst hvor modtageren (106) omfatter en radiofrekvenslæser, eller hvor modtageren (106) er konfigureret til at overføre informationer til det ikke-ledende kommunikationsmodul, eller hvor modtageren (106) er en komponent valgt fra et system udvalgt blandt gruppen bestående af fremstillingssystemer, styringssystemer for forsyningskæden og styringssystemer for sundhedspleje, helst hvor modtageren (106) er en komponent i et styringssystem, helst hvor modtageren (106) er associeret med en sorteringsenhed, eller hvor modtageren (106) er associeret med en kodningsenhed.
8. Systemet ifølge krav 6 eller 7, hvor modtageren (106) er en komponent i styringssystemet for forsyningskæden, helst hvor modtageren (106) er associeret med en sporingsenhed, eller hvor modtageren (106) er en komponent i styringssystemet for sundhedspleje, helst hvor modtageren (106) er associeret med en scanner, eller hvor modtageren (106) er associeret med en kodningsenhed.
9. Systemet ifølge ethvert af kravene 6-8, hvor modtageren (106) er konfigureret til det første signal, helst hvor det første signal omfatter ikke-fysiologiske data, helst hvor modtageren (106) er konfigureret til at blive aftageligt fastgjort på et levende menneske, helst hvor modtageren (106) omfatter en klæbende komponent, eller hvor modtageren (106) er en implanterbar modtager, eller hvor modtageren (106) er konfigureret som en elektrisk stimulationsenhed.
10. En metode omfattende: registrering af et første signal og/eller et andet signal fra en enhed (102) ifølge ethvert af de foregående krav 1-5.
DK11177516.9T 2002-04-05 2003-04-04 Farmaceutisk præparat indeholdende oxycodon og naloxon DK2425824T5 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10215131A DE10215131A1 (de) 2002-04-05 2002-04-05 Matrix zur verzögerten, gleichbleibenden und unabhängigen Freisetzung von Wirkstoffen
DE10215067A DE10215067A1 (de) 2002-04-05 2002-04-05 Lagerstabiles pharmazeutisches Präparat, das Oxycodon und Naloxon umfasst
EP03720424.5A EP1492505B1 (en) 2002-04-05 2003-04-04 Pharmaceutical preparation containing oxycodone and naloxone

Publications (2)

Publication Number Publication Date
DK2425824T3 true DK2425824T3 (da) 2017-08-28
DK2425824T5 DK2425824T5 (da) 2018-02-12

Family

ID=28676052

Family Applications (6)

Application Number Title Priority Date Filing Date
DK11177520.1T DK2425825T3 (da) 2002-04-05 2003-04-04 Farmaceutisk præparat indeholdende oxycodon og naloxon
DK03720425.2T DK1492506T4 (da) 2002-04-05 2003-04-04 Matrix for depot-, invariant- og uafhængig-frigørelse af aktive forbindelser
DK03720424.5T DK1492505T3 (da) 2002-04-05 2003-04-04 Farmaceutisk præparat indeholdende oxycodon og naloxon
DK11177516.9T DK2425824T5 (da) 2002-04-05 2003-04-04 Farmaceutisk præparat indeholdende oxycodon og naloxon
DK11177518.5T DK2425821T5 (da) 2002-04-05 2003-04-04 Farmaceutisk præparat indeholdende oxycodon og naloxon
DK200700243U DK200700243U3 (da) 2002-04-05 2007-09-18 Farmaceutisk præparat indeholdende oxycodon og naloxon

Family Applications Before (3)

Application Number Title Priority Date Filing Date
DK11177520.1T DK2425825T3 (da) 2002-04-05 2003-04-04 Farmaceutisk præparat indeholdende oxycodon og naloxon
DK03720425.2T DK1492506T4 (da) 2002-04-05 2003-04-04 Matrix for depot-, invariant- og uafhængig-frigørelse af aktive forbindelser
DK03720424.5T DK1492505T3 (da) 2002-04-05 2003-04-04 Farmaceutisk præparat indeholdende oxycodon og naloxon

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK11177518.5T DK2425821T5 (da) 2002-04-05 2003-04-04 Farmaceutisk præparat indeholdende oxycodon og naloxon
DK200700243U DK200700243U3 (da) 2002-04-05 2007-09-18 Farmaceutisk præparat indeholdende oxycodon og naloxon

Country Status (33)

Country Link
US (11) US20050245483A1 (da)
EP (17) EP2425824B1 (da)
JP (5) JP4620355B2 (da)
KR (3) KR100784341B1 (da)
CN (4) CN102813654A (da)
AP (2) AP2043A (da)
AR (3) AR039378A1 (da)
AT (1) ATE418967T2 (da)
AU (2) AU2003224041B2 (da)
BR (2) BRPI0309544B8 (da)
CA (3) CA2478515C (da)
CO (2) CO5611100A2 (da)
CY (5) CY1108914T1 (da)
DE (6) DE20308437U1 (da)
DK (6) DK2425825T3 (da)
ES (7) ES2546010T3 (da)
FI (1) FI7846U1 (da)
GE (3) GEP20084485B (da)
HK (5) HK1072367A1 (da)
HU (4) HUE032529T2 (da)
IL (5) IL163990A0 (da)
LT (3) LT2425824T (da)
MA (2) MA27249A1 (da)
MX (2) MXPA04009713A (da)
NZ (1) NZ535286A (da)
PH (1) PH12018000176A1 (da)
PT (5) PT2425825T (da)
RU (3) RU2297225C2 (da)
SI (5) SI2425821T1 (da)
TN (1) TNSN04192A1 (da)
TW (3) TWI337077B (da)
WO (2) WO2003084504A2 (da)
ZA (2) ZA200407267B (da)

Families Citing this family (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
RU2241458C2 (ru) 1997-12-22 2004-12-10 Эро-Селтик, С.А. Комбинации агонист/антагонист опиоида
EP2295043A1 (en) 1999-10-29 2011-03-16 Euro-Celtique S.A. Controlled release hydrocodone formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
JP2003522144A (ja) 2000-02-08 2003-07-22 ユーロ−セルティーク，エス．エイ． オピオイドアゴニストおよびアンタゴニストを含む制御放出組成物
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
CN101317825A (zh) 2000-10-30 2008-12-10 欧罗赛铁克股份有限公司 控释氢可酮制剂
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
CN1525851A (zh) 2001-05-11 2004-09-01 ������ҩ�����޹�˾ 抗滥用阿片样物质控释剂型
SI1416842T1 (sl) 2001-07-18 2009-06-30 Euro Celtique Sa Farmacevtske kombinacije oksikodona in naloksona
ES2326794T3 (es) 2001-08-06 2009-10-20 Euro-Celtique S.A. Formulaciones de agonistas opioides con antagonista liberable y secuestrado.
ES2546010T3 (es) 2002-04-05 2015-09-17 Euro-Celtique S.A. Preparación farmacéutica que contiene oxicodona y naloxona
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
PA8578501A1 (es) 2002-07-25 2005-02-04 Pharmacia Corp Forma de dosificacion una vez al dia de pramipexol
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US20060194826A1 (en) * 2003-09-25 2006-08-31 Euro-Celtique S.A. Pharmaceutical combinations of hydrocodone and naltrexone
GB0501638D0 (en) * 2005-01-28 2005-03-02 Euro Celtique Sa Particulates
TWI350762B (en) * 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
GB0403098D0 (en) 2004-02-12 2004-03-17 Euro Celtique Sa Extrusion
EP1604667A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
CN101849920A (zh) * 2004-08-13 2010-10-06 贝林格尔·英格海姆国际有限公司 包含普拉克索或其可药用盐的延长释放小球制剂、其制备方法及其用途
RS51527B2 (sr) 2004-08-13 2018-02-28 Boehringer Ingelheim Int Tabletna formulacija sa produženim otpuštanjem koja sadrži pramipeksol ili njegovu farmaceutski prihvatljivu so, postupak za proizvodnju iste i njena primena
CA2594373A1 (en) * 2005-01-28 2006-08-03 Euro-Celtique S.A. Alcohol resistant dosage forms
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
EP1695700A1 (en) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
EP1810678A1 (de) 2006-01-19 2007-07-25 Holger Lars Hermann Verwendung einer Kombination von Morphin und Naloxon zur Drogensubstitution
EP1813276A1 (en) * 2006-01-27 2007-08-01 Euro-Celtique S.A. Tamper resistant dosage forms
AU2011202866B2 (en) * 2006-01-27 2012-06-14 Mundipharma Pty Limited Tamper resistant dosage forms
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
DE202006018609U1 (de) * 2006-08-29 2007-05-16 Euro-Celtique S.A. Verwendung von Opioidformulierungen in nadellosen Vorrichtungen zur Medikamentenverabreichung
EP1897543A1 (en) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
US20080171762A1 (en) * 2007-01-16 2008-07-17 Ockert David M Treatment of pain with naloxone
DE102007011485A1 (de) * 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
CN105534936B (zh) * 2007-08-13 2020-07-31 Ohemo 生命科学股份有限公司 抗滥用药物、使用方法和制备方法
RU2007137044A (ru) * 2007-10-05 2009-04-10 Общество С Ограниченной Ответственностью "Концерн О3" (Ru) Лекарственное средство, обладающее гемопоэзстимулирующим и гепатопротекторным действием
CA2644179C (en) * 2007-11-21 2018-09-25 Pharmascience Inc. Novel pharmaceutical composition comprising a disintegration matrix
EP2249811A1 (en) 2008-01-25 2010-11-17 Grünenthal GmbH Pharmaceutical dosage form
HUE030803T2 (en) 2008-05-09 2017-06-28 Gruenenthal Gmbh Process for the preparation of an intermediate powder formulation and a final solid dosage form using a spraying step \ t
ES2635733T3 (es) * 2008-07-07 2017-10-04 Euro-Celtique S.A. Uso de antagonistas opioideos para tratar la retención urinaria
WO2010022193A2 (en) * 2008-08-20 2010-02-25 Board Of Regents, The University Of Texas System Hot-melt extrusion of modified release multi-particulates
RU2673882C1 (ru) 2008-10-30 2018-12-03 Грюненталь Гмбх Новые и эффективные лекарственные формы тапентадола
CA2750144C (en) 2008-12-31 2016-10-25 Upsher-Smith Laboratories, Inc. Opioid-containing oral pharmaceutical compositions and methods
SG174286A1 (en) 2009-03-10 2011-10-28 Euro Celtique Sa Immediate release pharmaceutical compositions comprising oxycodone and naloxone
GB0909680D0 (en) * 2009-06-05 2009-07-22 Euro Celtique Sa Dosage form
EP2456427B1 (en) 2009-07-22 2015-03-04 Grünenthal GmbH Hot-melt extruded controlled release dosage form
PE20120572A1 (es) 2009-07-22 2012-06-06 Gruenenthal Chemie Forma de dosificacion de oxidacion estabilizada resistente a la manipulacion
EP2477610A1 (en) 2009-09-17 2012-07-25 Upsher-Smith Laboratories, Inc. A sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti -inflammatory drug
US9125867B2 (en) * 2010-02-24 2015-09-08 Invincible Biotechnology Diversion- and/or abuse-resistant compositions and methods for making the same
CA2798885C (en) 2010-05-10 2014-11-18 Euro-Celtique S.A. Combination of active loaded granules with additional actives
CH705273B1 (de) 2010-05-10 2016-06-15 Euro Celtique Sa Pharmazeutische Zusammensetzung – umfassend Hydromorphon und Naloxon.
AU2011252040C1 (en) 2010-05-10 2015-04-02 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
MX2012012991A (es) 2010-05-11 2012-11-30 Cima Labs Inc Formas de dosificacion oral de liberacion prolongada resistentes al alcohol y que contienen metoprolol.
EP2600877A4 (en) 2010-08-04 2014-05-07 Borody Thomas J COMPOSITIONS FOR FLORAL TRANSPLANTATION OF FECAL MATERIALS AND METHODS OF MAKING AND USING SAME, AND DEVICES FOR THEIR ADMINISTRATION
CH705678B1 (de) * 2010-08-13 2016-03-15 Euro Celtique Sa Verwendung von Bindemitteln zur Herstellung von lagerungsstabilen Formulierungen.
PE20131126A1 (es) 2010-09-02 2013-10-21 Gruenenthal Chemie Forma de dosificacion resistente a alteracion que comprende un polimero anionico
NZ607392A (en) 2010-09-02 2015-03-27 Gruenenthal Chemie Tamper resistant dosage form comprising inorganic salt
US9012469B2 (en) 2010-09-30 2015-04-21 Astrazeneca Ab Crystalline naloxol-peg conjugate
MX355760B (es) 2010-12-13 2018-04-27 Salix Pharmaceuticals Inc Formulaciones gástricas y colónicas y métodos para elaborar y usar las mismas.
CN103561752B (zh) 2011-03-09 2016-04-20 明尼苏达大学评议会 用于移植结肠微生物群的组合物和方法
AT511581A1 (de) 2011-05-26 2012-12-15 G L Pharma Gmbh Orale retardierende formulierung
DK2736497T3 (da) 2011-07-29 2017-11-13 Gruenenthal Gmbh Stød-resistent tablet, der tilvejebringer en øjeblikkelig frigivelse af et lægemiddel.
EP2736495B1 (en) 2011-07-29 2017-08-23 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
WO2013030226A2 (en) * 2011-08-29 2013-03-07 Dsm Ip Assets B.V. Laboratory extruder
AR088250A1 (es) 2011-10-06 2014-05-21 Gruenenthal Gmbh Forma de dosificacion farmaceutica oral resistente a alteracion comprendiendo agonista opioide y antagonista opioide
WO2013072395A1 (en) 2011-11-17 2013-05-23 Grünenthal GmbH Tamper-resistant oral pharmaceutical dosage form comprising a pharmacologically active ingredient, an opioid antagonist and/or aversive agent, polyalkylene oxide and anionic polymer
MX356421B (es) 2012-02-28 2018-05-29 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
CN110101702A (zh) 2012-04-17 2019-08-09 普渡制药公司 用于治疗阿片样物质所致不良药效学响应的系统和方法
LT2838512T (lt) 2012-04-18 2018-11-12 GrĆ¼nenthal GmbH Pažeidimui atspari ir dozės atpalaidavimo nuokrypiui atspari farmacinė vaisto forma
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US9719144B2 (en) 2012-05-25 2017-08-01 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
NZ703394A (en) 2012-06-04 2017-01-27 Centre For Digestive Diseases Compositions and methods for treating crohn’s disease and related conditions and infections
CA2880282C (en) 2012-07-27 2020-09-01 Redhill Biopharma Ltd. Formulations and methods of manufacturing formulations for use in colonic evacuation
US10485798B2 (en) 2012-08-22 2019-11-26 Aptapharma Inc. Methylnaltrexone nasal formulations, methods of making, and use thereof
MX2015007518A (es) * 2012-12-14 2016-03-01 Trevi Therapeutics Inc Metodos para tratar el prurito.
US11571390B2 (en) 2013-03-15 2023-02-07 Othemo Life Sciences, Inc. Abuse deterrent compositions and methods of use
EP2991649B1 (en) 2013-04-30 2020-06-03 Thomas Julius Borody Compositions for treating obsessive-compulsive disorder
US20160244459A1 (en) 2013-05-24 2016-08-25 Rhodes Technologies Opioid ketal compounds and uses thereof
US10154966B2 (en) 2013-05-29 2018-12-18 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
MX2015016254A (es) 2013-05-29 2016-04-20 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido con perfil de liberacion bimodal.
KR20160031526A (ko) 2013-07-12 2016-03-22 그뤼넨탈 게엠베하 에틸렌-비닐 아세테이트 중합체를 함유하는 템퍼 내성 투여형
NZ716267A (en) 2013-07-23 2017-05-26 Euro Celtique Sa A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
WO2015065547A1 (en) 2013-10-31 2015-05-07 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
CN105916505A (zh) 2013-11-13 2016-08-31 欧洲凯尔特公司 用于治疗疼痛和阿片样物质肠功能障碍综合征的氢吗啡酮和纳洛酮
CA2931553C (en) 2013-11-26 2022-01-18 Grunenthal Gmbh Preparation of a powdery pharmaceutical composition by means of cryo-milling
US9456986B2 (en) 2013-12-11 2016-10-04 Develco Pharma Schweiz Ag Naloxone mono preparation and multilayer tablet
US10105360B2 (en) 2013-12-11 2018-10-23 Develco Pharma Schweiz Ag Method and composition for the treatment of opioid induced constipation
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095644A1 (en) 2013-12-20 2015-06-25 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
US10085937B2 (en) 2014-03-14 2018-10-02 Adapt Pharma Limited Nasal drug products and methods of their use
US9480644B2 (en) 2014-03-14 2016-11-01 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
US9561177B2 (en) 2014-03-14 2017-02-07 Adapt Pharma Limited Nasal drug products and methods of their use
RU2020112530A (ru) 2014-03-14 2021-07-21 ОПИАНТ ФАРМАСЮТИКАЛС, Инк. Назальные готовые лекарственные формы и способы их применения
EP3142646A1 (en) 2014-05-12 2017-03-22 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
US9872835B2 (en) 2014-05-26 2018-01-23 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
EP3169315B1 (en) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
EP3229785A2 (de) * 2014-12-08 2017-10-18 Develco Pharma Schweiz AG Naloxon-monopräparat und mehrschichttablette
WO2016170097A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
CN107949391B (zh) 2015-05-14 2021-11-09 克雷斯顿沃控股公司 用于粪便菌群移植的组合物以及用于制备和使用它们的方法和用于递送它们的装置
EP3297644B1 (en) 2015-05-22 2022-01-19 Arizona Board of Regents on behalf of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
WO2017042325A1 (en) 2015-09-10 2017-03-16 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
EP3352773A4 (en) 2015-09-24 2019-03-27 San Diego State University (SDSU) Foundation DBA San Diego State University Research Foundation ANTIBACTERIAL AND PROTECTIVE BACTERIOPHAGE FORMULATIONS AND PROCESS FOR THE PREPARATION AND USE THEREOF
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US10624888B2 (en) * 2016-03-31 2020-04-21 SpecGx LLC Extended release, abuse deterrent dosage forms
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
EP3290027A1 (en) * 2016-09-02 2018-03-07 Develco Pharma Schweiz AG Method and composition for the treatment of opioid induced constipation
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
WO2018071537A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
WO2018071536A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating primary sclerosing cholangitis and related disorders
WO2018187464A1 (en) 2017-04-05 2018-10-11 Crestovo Holdings Llc Compositions and methods for treating diverticulitis and related disorders
CA3058818A1 (en) 2017-04-05 2018-10-11 Crestovo Holdings Llc Compositions and methods for treating parkinson's disease (pd) and related disorders
AU2018272048B2 (en) 2017-05-26 2024-04-04 Finch Therapeutics Holdings Llc Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
KR20200038506A (ko) 2017-08-07 2020-04-13 핀치 테라퓨틱스, 인코포레이티드 건강한 장 장벽을 유지 및 회복시키기 위한 조성물 및 방법
WO2019152002A1 (en) * 2018-01-31 2019-08-08 Dharma Laboratories LLC Non-extractable oral solid dosage forms
US10624856B2 (en) 2018-01-31 2020-04-21 Dharma Laboratories LLC Non-extractable oral solid dosage forms
EP3755704A1 (en) 2018-02-23 2020-12-30 Rhodes Technologies Inc. Novel opioid compounds and uses thereof
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
WO2020023486A1 (en) 2018-07-23 2020-01-30 Trevi Therapeutics, Inc. Treatment of chronic cough, breathlessness and dyspnea
WO2020069280A1 (en) 2018-09-27 2020-04-02 Crestovo Holdings Llc Compositions and methods for treating epilepsy and related disorders
WO2020225773A1 (en) 2019-05-07 2020-11-12 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine

Family Cites Families (278)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2770569A (en) 1952-08-01 1956-11-13 Hoffmann La Roche Analgesic compositions
US3173877A (en) 1957-09-09 1965-03-16 Wyandotte Chemicals Corp Detergent compositions comprising inorganic esters of epoxyhydrocarbon polymers
US3173876A (en) * 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
NL271831A (da) * 1960-11-29
US3493657A (en) 1961-03-14 1970-02-03 Mozes Juda Lewenstein Therapeutic compositions of n-allyl-14-hydroxy - dihydronormorphinane and morphine
US3332950A (en) 1963-03-23 1967-07-25 Endo Lab 14-hydroxydihydronormorphinone derivatives
US3276586A (en) * 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
NL6714885A (da) * 1967-11-02 1969-05-06
US3541006A (en) * 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) * 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US3773955A (en) 1970-08-03 1973-11-20 Bristol Myers Co Analgetic compositions
US3879555A (en) 1970-11-16 1975-04-22 Bristol Myers Co Method of treating drug addicts
US3676557A (en) 1971-03-02 1972-07-11 Endo Lab Long-acting narcotic antagonist formulations
GB1390772A (en) 1971-05-07 1975-04-16 Endo Lab Oral narcotic composition
FR2183546B1 (da) * 1972-05-10 1975-06-20 Servier Lab
US3965256A (en) 1972-05-16 1976-06-22 Synergistics Slow release pharmaceutical compositions
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3916889A (en) * 1973-09-28 1975-11-04 Sandoz Ag Patient ventilator apparatus
US3966940A (en) 1973-11-09 1976-06-29 Bristol-Myers Company Analgetic compositions
GB1478759A (en) * 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US3966040A (en) * 1975-03-05 1976-06-29 Hazelwood John E Combined vibratory feeder drive unit, vibratory feeder bowl, and parts separator
US4077407A (en) * 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4126684A (en) * 1976-02-11 1978-11-21 Ciba-Geigy Corporation 4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse
US4063064A (en) * 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
LU77339A1 (da) 1977-05-16 1979-01-19
US4176186A (en) 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
US4200098A (en) * 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4285987A (en) * 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4237140A (en) 1979-05-18 1980-12-02 E. I. Du Pont De Nemours And Company Analgesic mixture of nalbuphine and acetaminophen
US4293539A (en) 1979-09-12 1981-10-06 Eli Lilly And Company Controlled release formulations and method of treatment
IE49324B1 (en) 1979-12-19 1985-09-18 Euro Celtique Sa Controlled release compositions
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
US4464378A (en) 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4401672A (en) 1981-10-13 1983-08-30 Regents Of The University Of Minnesota Non-addictive narcotic antitussive preparation
US4608376A (en) 1981-10-16 1986-08-26 Carolyn McGinnis Opiate agonists and antagonists
US4987136A (en) 1982-03-16 1991-01-22 The Rockefeller University Method for controlling gastrointestinal dysmotility
JPS59500418A (ja) * 1982-03-16 1984-03-15 ザ　ロツクフエラ−　ユニバ−シテイ 胃腸能動作用障害を回復する方法
US4443428A (en) 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
US4451470A (en) 1982-07-06 1984-05-29 E. I. Du Pont De Nemours And Company Analgesic, antagonist, and/or anorectic 14-fluoromorphinans
US4803208A (en) 1982-09-30 1989-02-07 Sloan-Kettering Institute For Cancer Research Opiate agonists and antagonists
GB8332556D0 (en) 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US5266574A (en) 1984-04-09 1993-11-30 Ian S. Zagon Growth regulation and related applications of opioid antagonists
US4668685A (en) * 1984-07-05 1987-05-26 E.I. Du Pont De Nemours And Company Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
US4626539A (en) * 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
DE3434946A1 (de) 1984-09-22 1986-04-03 Basf Ag, 6700 Ludwigshafen Diarylacetylene, ihre herstellung und verwendung
US4573995A (en) 1984-10-09 1986-03-04 Alza Corporation Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine
GB8430346D0 (en) 1984-11-30 1985-01-09 Reckitt & Colmann Prod Ltd Analgesic compositions
US4806341A (en) 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
ZA861211B (en) 1985-02-25 1987-10-28 Lilly Co Eli Analgesic composition
JPS61280423A (ja) 1985-06-05 1986-12-11 Kiyuukiyuu Yakuhin Kogyo Kk 口腔内粘膜貼付剤
GB8514665D0 (en) 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
FR2585246A1 (fr) 1985-07-26 1987-01-30 Cortial Procede d'obtention de formes pharmaceutiques solides a liberation prolongee
GB8521350D0 (en) 1985-08-28 1985-10-02 Euro Celtique Sa Analgesic composition
JPS63500799A (ja) 1985-09-06 1988-03-24 ベーカー・カミンス・ファーマシューティカルス・インコーポレーテッド 持続性オピオイド拮抗作用を得るための方法および組成物
US4889860A (en) 1985-09-23 1989-12-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
US4760069A (en) 1985-09-23 1988-07-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
US4722928A (en) 1985-12-02 1988-02-02 E. I. Du Pont De Nemours And Company N-oxide prodrug derivatives of 3-hydroxy morphinans and partial morphinans having improved oral bioavailability, pharmaceutical compositions, and processes
US4730048A (en) 1985-12-12 1988-03-08 Regents Of The University Of Minnesota Gut-selective opiates
US4861781A (en) 1986-03-07 1989-08-29 The University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US4719215A (en) 1986-03-07 1988-01-12 University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US5316759A (en) 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
GB8613688D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
GB8613689D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
EP0249347B1 (en) 1986-06-10 1994-06-29 Euroceltique S.A. Controlled release dihydrocodeine composition
US4785000A (en) 1986-06-18 1988-11-15 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US4769372A (en) 1986-06-18 1988-09-06 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US4861598A (en) * 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4970075A (en) 1986-07-18 1990-11-13 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US5356900A (en) 1986-10-07 1994-10-18 Bernard Bihari Method of treating chronic herpes virus infections using an opiate receptor antagonist
GB8626098D0 (en) 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US4806543A (en) 1986-11-25 1989-02-21 Board Of Trustees Of The Leland Stanford Junior University Method and compositions for reducing neurotoxic injury
GB8628728D0 (en) 1986-12-02 1987-01-07 Euro Celtique Sa Spheroids
GB8705083D0 (en) 1987-03-04 1987-04-08 Euro Celtique Sa Spheroids
GB8728294D0 (en) 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
DE3812567A1 (de) * 1988-04-15 1989-10-26 Basf Ag Verfahren zur herstellung pharmazeutischer mischungen
US4873076A (en) 1988-04-29 1989-10-10 Baker Cummins Pharmaceuticals, Inc. Method of safely providing anesthesia or conscious sedation
GB8813064D0 (en) 1988-06-02 1988-07-06 Euro Celtique Sa Controlled release dosage forms having defined water content
US4882335A (en) 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response
EP0352361A1 (en) 1988-07-29 1990-01-31 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US5236714A (en) 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
CA2002492A1 (en) 1988-11-11 1990-05-11 Sandra T. A. Malkowska Pharmaceutical ion exchange resin composition
US5102887A (en) 1989-02-17 1992-04-07 Arch Development Corporation Method for reducing emesis and nausea induced by the administration of an emesis causing agent
US5096715A (en) 1989-11-20 1992-03-17 Alko Ltd. Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist
US5075341A (en) 1989-12-01 1991-12-24 The Mclean Hospital Corporation Treatment for cocaine abuse
US5086058A (en) 1990-06-04 1992-02-04 Alko Ltd. Method for treating alcoholism with nalmefene
FR2669336B1 (fr) 1990-11-20 1993-01-22 Adir Nouveaux derives d'oxazolo pyridines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
HU208633B (en) 1991-02-04 1993-12-28 Alkaloida Vegyeszeti Gyar Process for production of analgetic compositions as applicable for blocking of opioid-binding spaces /2-receptors/ causing respiration depression
US5486362A (en) 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
JP3178541B2 (ja) 1991-05-29 2001-06-18 キヤノン株式会社 画像処理方法及び装置
US5149538A (en) 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
GB9117361D0 (en) * 1991-08-12 1991-09-25 Euro Celtique Sa Oral dosage form
KR100221695B1 (ko) * 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 약학적 구상 제형
CA2095523C (en) 1991-09-06 2004-06-22 Robert B. Raffa Composition comprising a tramadol material and acetaminophen and its use
US5215758A (en) 1991-09-11 1993-06-01 Euroceltique, S.A. Controlled release matrix suppository for pharmaceuticals
US5225440A (en) 1991-09-13 1993-07-06 The United States Of America As Represented By The Department Of Health And Human Services Attenuation of the opioid withdrawal syndrome by inhibitors of nitric oxide synthase
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5478577A (en) 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5273760A (en) * 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5958459A (en) 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
GB9203689D0 (en) 1992-02-20 1992-04-08 Euro Celtique Sa Pharmaceutical composition
GB9204354D0 (en) 1992-02-28 1992-04-08 Biokine Tech Ltd Compounds for medicinal use
ATE404201T1 (de) 1992-06-22 2008-08-15 Univ California Glycinrezeptorantagonisten und ihre verwendung
US5352680A (en) 1992-07-15 1994-10-04 Regents Of The University Of Minnesota Delta opioid receptor antagonists to block opioid agonist tolerance and dependence
US5256669A (en) 1992-08-07 1993-10-26 Aminotek Sciences, Inc. Methods and compositions for treating acute or chronic pain and drug addiction
US5324351A (en) * 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
US5633259A (en) 1992-09-21 1997-05-27 United Biomedical, Inc. Method for identification of low/non-addictive opioid analgesics and the use of said analgesics for treatment of opioid addiction
US5512578A (en) 1992-09-21 1996-04-30 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists
US20010006967A1 (en) 1992-09-21 2001-07-05 Stanley M. Crain Method of simultaneously enhancing analgesic potency and attenuating adverse side effects caused by tramadol and other bimodally-acting opioid agonists
US6096756A (en) 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5472943A (en) 1992-09-21 1995-12-05 Albert Einstein College Of Medicine Of Yeshiva University, Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists
JPH08504189A (ja) 1992-09-21 1996-05-07 キン、ボーイ 低／非たんでき性オピオイド鎮痛剤の確認及び使用方法
US5580876A (en) 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5869097A (en) 1992-11-02 1999-02-09 Alza Corporation Method of therapy comprising an osmotic caplet
US5604260A (en) 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
US5321012A (en) 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
US5585348A (en) 1993-02-10 1996-12-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Use of excitatory opioid receptor antagonists to prevent growth factor-induced hyperalgesia
CA2115792C (en) 1993-03-05 2005-11-01 David J. Mayer Method for the treatment of pain
US5352683A (en) 1993-03-05 1994-10-04 Virginia Commonwealth University Medical College Of Virginia Method for the treatment of chronic pain
US5409944A (en) 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
IL119660A (en) * 1993-05-10 2002-09-12 Euro Celtique Sa Controlled release formulation comprising tramadol
US5457208A (en) 1993-06-21 1995-10-10 Regents Of The University Of Minnesota Kappa opioid receptor antagonists
US5436265A (en) 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
CN1230154C (zh) * 1993-07-01 2005-12-07 欧洲凯尔特公司 缓释组合物及制备药用组合物的方法
NZ260883A (en) 1993-07-01 1997-06-24 Euro Celtique Sa Oral sustained-release medicaments containing morphine
US5879705A (en) 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
DE4325465B4 (de) 1993-07-29 2004-03-04 Zenz, Michael, Prof. Dr.med. Orales pharmazeutisches Präparat für die Schmerztherapie
GB9319568D0 (en) 1993-09-22 1993-11-10 Euro Celtique Sa Pharmaceutical compositions and usages
EP1442745A1 (en) 1993-10-07 2004-08-04 Euro-Celtique Orally administrable opioid formulations having extended duration of effect
US5891471A (en) 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US5500227A (en) 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
KR100354702B1 (ko) 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
ES2168290T3 (es) 1993-11-23 2002-06-16 Euro Celtique Sa Metodo para preparar una composicion de liberacion sostenida.
US6210714B1 (en) 1993-11-23 2001-04-03 Euro-Celtique S.A. Immediate release tablet cores of acetaminophen having sustained-release coating
US5376662A (en) 1993-12-08 1994-12-27 Ockert; David M. Method of attenuating nerve injury induced pain
US5834477A (en) 1993-12-08 1998-11-10 The United States Of America As Represented By The Secretary Of The Army Opiate analgesic formulation with improved safety
US5843480A (en) 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
US6077533A (en) 1994-05-25 2000-06-20 Purdue Pharma L.P. Powder-layered oral dosage forms
US5411745A (en) * 1994-05-25 1995-05-02 Euro-Celtique, S.A. Powder-layered morphine sulfate formulations
US5958458A (en) * 1994-06-15 1999-09-28 Dumex-Alpharma A/S Pharmaceutical multiple unit particulate formulation in the form of coated cores
US5460826A (en) 1994-06-27 1995-10-24 Alza Corporation Morphine therapy
GB9414699D0 (en) 1994-07-21 1994-09-07 Slagel David Aqueous foamable composition
US5616601A (en) 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5593994A (en) 1994-09-29 1997-01-14 The Dupont Merck Pharmaceutical Company Prostaglandin synthase inhibitors
US5866154A (en) * 1994-10-07 1999-02-02 The Dupont Merck Pharmaceutical Company Stabilized naloxone formulations
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
CA2206119C (en) 1994-12-12 2008-05-13 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain, inflammation and spasm
GB9426102D0 (en) 1994-12-23 1995-02-22 Merck Sharp & Dohme Pharmacuetical compositions
US5692500A (en) 1995-01-09 1997-12-02 Gaston-Johansson; Fannie Pain measurement and recording tool and method
US5552422A (en) 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
US5578725A (en) 1995-01-30 1996-11-26 Regents Of The University Of Minnesota Delta opioid receptor antagonists
US20020006964A1 (en) * 1995-05-16 2002-01-17 Young James W. Methods of using and compositions comprising (+) sibutramine optionally in combination with other pharmacologically active compounds
US5604253A (en) 1995-05-22 1997-02-18 Merck Frosst Canada, Inc. N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
US5639780A (en) 1995-05-22 1997-06-17 Merck Frosst Canada, Inc. N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
US5510368A (en) 1995-05-22 1996-04-23 Merck Frosst Canada, Inc. N-benzyl-3-indoleacetic acids as antiinflammatory drugs
CA2195119C (en) 1995-06-09 2001-09-11 Mark Chasin Formulations and methods for providing prolonged local anesthesia
US5931809A (en) 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
GB9517062D0 (en) * 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
GB9517883D0 (en) 1995-09-01 1995-11-01 Euro Celtique Sa Improved pharmaceutical ion exchange resin composition
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
US5811126A (en) 1995-10-02 1998-09-22 Euro-Celtique, S.A. Controlled release matrix for pharmaceuticals
AUPN603895A0 (en) 1995-10-19 1995-11-09 University Of Queensland, The Production of analgesic synergy by co-administration of sub-analgesic doses of two strong opioids
US5998434A (en) 1995-12-06 1999-12-07 Eli Lilly And Company Composition for treating pain
US6159501A (en) 1996-03-08 2000-12-12 Nycomed Danmark A/S Modified release multiple-units dosage composition for release of opioid compounds
WO1997033566A2 (en) 1996-03-12 1997-09-18 Alza Corporation Composition and dosage form comprising opioid antagonist
US6103258A (en) 1996-04-12 2000-08-15 Simon; David Lew Salts and bases of the 17-(Cyclopropylmethyl)-4,5 alpha-epoxy-6-Methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics
JPH11508608A (ja) * 1996-04-17 1999-07-27 ニューロクライン バイオサイエンシーズ，インコーポレイテッド インスリン様成長因子結合タンパク質のリガンドインヒビターおよびそれらの使用方法
WO1997045091A2 (en) * 1996-05-31 1997-12-04 Euro-Celtique, S.A. Sustained release oxycodone formulations with no fed/fast effect
WO1998024412A2 (en) * 1996-12-05 1998-06-11 The Board Of Trustees Of The University Of Illinois Compounds useful against diseases of the colon and methods for orally administering same
DE19651551C2 (de) 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioidantagonisthaltige galenische Formulierung
DE29719704U1 (de) 1997-02-14 1998-01-22 Goedecke Ag Stabile Zubereitungen von Naloxonhydrochlorid
ATE186643T1 (de) 1997-02-14 1999-12-15 Goedecke Ag Stabilisierung von naloxonhydrochlorid
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
DE19710008A1 (de) 1997-03-12 1998-09-17 Basf Ag Feste, mindestens zweiphasige Zubereitungsformen eines Opioid-Analgeticums mit verzögerter Freisetzung
US5780479A (en) 1997-04-04 1998-07-14 Regents Of The University Of Minnesota Use of opioid antagonists to treat impulse-control disorders
US6207142B1 (en) * 1997-04-14 2001-03-27 Janssen Pharmaceutica N.V. Compositions containing an antifungal and a cationic agent
PT1009387E (pt) * 1997-07-02 2006-08-31 Euro Celtique Sa Formulacoes estabilizadas de libertacao controlada de tramadol
AU3690297A (en) 1997-07-30 1999-02-22 Universite De Montreal Portable and programmable interactive visual analogue scale data-logger device
EP2246058A1 (en) 1997-09-04 2010-11-03 Novoneuron, Inc. Noribogaine in the treatment of pain and drug addiction
ATE210983T1 (de) 1997-11-03 2002-01-15 Stada Arzneimittel Ag Stabilisiertes kombinationsarzneimittel enthaltend naloxone und ein opiatanalgetikum
US5972954A (en) 1997-11-03 1999-10-26 Arch Development Corporation Use of methylnaltrexone and related compounds
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
CN1204890C (zh) * 1997-12-22 2005-06-08 欧罗赛铁克股份有限公司 防止阿片样物质滥用的方法
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
RU2241458C2 (ru) 1997-12-22 2004-12-10 Эро-Селтик, С.А. Комбинации агонист/антагонист опиоида
HUP0101954A3 (en) * 1998-03-27 2002-09-30 Upjohn Co Use of cabergoline in the production of pharmaceutical compositions for the treatment of restless legs syndrome
US5957459A (en) 1998-04-27 1999-09-28 Chae; Myung Joo Banking card game
DE19857766A1 (de) 1998-05-28 1999-12-02 Krewel Meuselbach Gmbh Retardiertes Schmerzmittel enthaltend Tilidin
ATE261302T1 (de) 1998-05-28 2004-03-15 Krewel Meuselbach Gmbh Retardiertes schmerzmittel enthaltend tilidin
DE29818454U1 (de) 1998-10-15 1999-01-14 Euro Celtique Sa Opioid-Analgetikum
SE9803760D0 (sv) 1998-11-04 1998-11-04 Jan Hedner Sätt att behandla och diagnostisera syndromet restless legs och motsvarande medel
FR2787715B1 (fr) 1998-12-23 2002-05-10 Synthelabo Composition pharmaceutique comprenant un compose hypnotique ou un de ses sels pharmaceutiquement acceptables
DE19859636A1 (de) 1998-12-23 2000-06-29 Hexal Ag Kontrolliert freisetzende pharmazeutische Zusammensetzung mit Tilidinmesylat als Wirkstoff
DE19901085C2 (de) 1999-01-14 2003-12-18 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit einer selbstklebenden Matrix, enthaltend organische Säure-Additionssalze von Alkaloiden des Morphin- bzw. Morphinantyps
US6194382B1 (en) 1999-03-03 2001-02-27 Albert Einstein College Of Medicine Of Yeshiva University Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
US6765010B2 (en) 1999-05-06 2004-07-20 Pain Therapeutics, Inc. Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects
US20030178031A1 (en) * 1999-05-07 2003-09-25 Du Pen, Inc. Method for cancer pain treatment
US6419595B1 (en) 1999-07-09 2002-07-16 Bridgestone Sports Co., Ltd. Solid golf ball
US6451007B1 (en) 1999-07-29 2002-09-17 Dale E. Koop Thermal quenching of tissue
US20030118641A1 (en) * 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
DE19938823A1 (de) * 1999-08-19 2001-02-22 Boehringer Ingelheim Pharma Medikamentöse Behandlung des Restless Leg Syndroms
US6258042B1 (en) * 1999-09-17 2001-07-10 James S. Factor Visual analog scale and method of use for the diagnosis and/or treatment of physical pain
US6451806B2 (en) 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
EP1225897B1 (en) 1999-11-01 2004-09-08 RHODES, John Composition for treatment of constipation and irritable bowel syndrome
WO2001037785A2 (en) 1999-11-29 2001-05-31 Adolor Corporation Novel methods and compositions involving opioids and antagonists thereof
WO2001052851A1 (en) 2000-01-22 2001-07-26 Albert Shulman Methods for the treatment of substance abuse
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
JP2003522144A (ja) 2000-02-08 2003-07-22 ユーロ−セルティーク，エス．エイ． オピオイドアゴニストおよびアンタゴニストを含む制御放出組成物
ATE326222T1 (de) 2000-03-15 2006-06-15 Wolfgang Sadee Naloxon- und naltrexon-analoga in der behandlung bei drogenmissbrauch
WO2001085150A2 (en) 2000-05-05 2001-11-15 Pain Therapeutics, Inc. Opioid antagonist containing composition for enchaching the potency or reducing adverse side effects ofopioid agonists
JP2004515455A (ja) 2000-05-05 2004-05-27 ペイン・セラピューティクス・インコーポレイテッド オピオイドアンタゴニスト組成物および投薬形態
WO2001093852A2 (en) 2000-06-09 2001-12-13 The Regents Of The University Of California Method of treating pain using nalbuphine and opioid antagonists
US7223421B2 (en) * 2000-06-30 2007-05-29 Mcneil-Ppc, Inc. Teste masked pharmaceutical particles
GB0026137D0 (en) 2000-10-25 2000-12-13 Euro Celtique Sa Transdermal dosage form
AR031152A1 (es) * 2000-10-31 2003-09-10 Upjohn Co Tratamientos nuevos para el sindrome de piernas inquietas
AP2002002521A0 (en) * 2001-04-19 2002-06-30 Warner Lambert Co Fused bicyclic or tricyclic amino acids.
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
CN1525851A (zh) 2001-05-11 2004-09-01 ������ҩ�����޹�˾ 抗滥用阿片样物质控释剂型
US20030004177A1 (en) * 2001-05-11 2003-01-02 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form
DE10131113A1 (de) 2001-06-28 2003-01-23 Siemens Linear Motor Systems G Rotations-Elektromotor
WO2003004009A1 (en) 2001-07-02 2003-01-16 Geneva Pharmaceuticals, Inc. Pharmaceutical composition
SI1416842T1 (sl) 2001-07-18 2009-06-30 Euro Celtique Sa Farmacevtske kombinacije oksikodona in naloksona
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US7144587B2 (en) * 2001-08-06 2006-12-05 Euro-Celtique S.A. Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
BR0212020A (pt) 2001-08-06 2005-08-16 Euro Celtique Sa Formas de dosagem, métodos para impedir o abuso de uma forma de dosagem, métodos para impedir o desvio de uma forma de dosagem, métodos para o tratamento de dor e método de preparação de uma forma de dosagem
US20030157168A1 (en) 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
ES2326794T3 (es) 2001-08-06 2009-10-20 Euro-Celtique S.A. Formulaciones de agonistas opioides con antagonista liberable y secuestrado.
US7332182B2 (en) * 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
KR20040060917A (ko) 2001-08-06 2004-07-06 유로-셀티크 소시에떼 아노뉨 오피오이드 남용을 방지하기 위한 조성물 및 방법
EP1427476B1 (en) 2001-09-06 2009-03-25 Hans Gregersen Apparatus for stimulating a bodily hollow system and for measuring reactions to stimuli of such system
US20040253310A1 (en) * 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
US20040234602A1 (en) * 2001-09-21 2004-11-25 Gina Fischer Polymer release system
US20030092759A1 (en) * 2001-09-24 2003-05-15 Abuzzahab Faruk S. Anticonvulsant derivatives useful for the treatment of restless limb syndrome and periodic limb movement disorder
SI1482835T1 (sl) 2002-03-06 2013-02-28 Euro-Celtique S.A. Analogna lestvica za merjenje bolečine
WO2003077867A2 (en) 2002-03-14 2003-09-25 Euro-Celtique, S.A. Naltrexone hydrochloride compositions
ES2546010T3 (es) 2002-04-05 2015-09-17 Euro-Celtique S.A. Preparación farmacéutica que contiene oxicodona y naloxona
DE10215067A1 (de) 2002-04-05 2003-10-16 Euro Celtique Sa Lagerstabiles pharmazeutisches Präparat, das Oxycodon und Naloxon umfasst
DE10215131A1 (de) 2002-04-05 2003-10-16 Euro Celtique Sa Matrix zur verzögerten, gleichbleibenden und unabhängigen Freisetzung von Wirkstoffen
US20030191147A1 (en) * 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
EP1364649A1 (en) 2002-05-23 2003-11-26 Cilag AG Adduct of topiramate and tramadol hydrochioride and uses thereof
WO2004004693A1 (en) * 2002-07-05 2004-01-15 Collgegium Pharmaceutical Abuse-deterrent pharmaceutical compositions of opiods and other drugs
RU2222260C1 (ru) 2002-07-08 2004-01-27 Сибирский государственный медицинский университет Способ дифференцированной оценки степени функциональной активности тонкой кишки
JP5189242B2 (ja) 2002-09-23 2013-04-24 アルケルメス ファーマ アイルランド リミテッド 乱用抵抗性の医薬組成物
US20060153915A1 (en) 2003-01-23 2006-07-13 Amorepacific Corporation Sustained-release preparations and method for producing the same
DK2368553T3 (da) 2003-04-08 2015-02-09 Progenics Pharm Inc Lægemiddelsammensætning der omfatter methylnaltrexon
TWI357815B (en) 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates
US20050053659A1 (en) 2003-09-10 2005-03-10 Pace Gary W. Methods and compositions for reducing the risk associated with the administration of opioid analgesics in patients with diagnosed or undiagnosed respiratory illness
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
US7700626B2 (en) * 2004-06-04 2010-04-20 Adolor Corporation Compositions containing opioid antagonists
EP1604666A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1604667A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
GB2418854B (en) 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
CA2594373A1 (en) 2005-01-28 2006-08-03 Euro-Celtique S.A. Alcohol resistant dosage forms
EP1695700A1 (en) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
US20070092576A1 (en) 2005-10-20 2007-04-26 Adolor Corporation Compositions containing opioid antagonists
EP1813276A1 (en) 2006-01-27 2007-08-01 Euro-Celtique S.A. Tamper resistant dosage forms
US20070185145A1 (en) 2006-02-03 2007-08-09 Royds Robert B Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same
WO2007111945A2 (en) 2006-03-22 2007-10-04 Trustees Of Boston University Method for management of diarrhea
AU2007240873A1 (en) 2006-04-19 2007-11-01 Jill P. Smith Treatment of inflammatory and ulcerative diseases of the bowel with opioid antagonists
DE202006018609U1 (de) 2006-08-29 2007-05-16 Euro-Celtique S.A. Verwendung von Opioidformulierungen in nadellosen Vorrichtungen zur Medikamentenverabreichung
TW200817048A (en) 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
EP2042176A1 (en) 2007-09-26 2009-04-01 Euro-Celtique S.A. Use of a combination of an opioid agonist and an opioid antagonist for the treatment of Crohn's disease
ES2635733T3 (es) 2008-07-07 2017-10-04 Euro-Celtique S.A. Uso de antagonistas opioideos para tratar la retención urinaria
SG174286A1 (en) 2009-03-10 2011-10-28 Euro Celtique Sa Immediate release pharmaceutical compositions comprising oxycodone and naloxone
NO330672B1 (no) 2009-11-12 2011-06-06 Proxdynamics As Rotormekanisme for helikoptere
CH705678B1 (de) 2010-08-13 2016-03-15 Euro Celtique Sa Verwendung von Bindemitteln zur Herstellung von lagerungsstabilen Formulierungen.

Also Published As

Publication number Publication date
US20120108621A1 (en) 2012-05-03
DE20308437U1 (de) 2003-11-13
ES2546010T3 (es) 2015-09-17
RU2004131870A (ru) 2005-05-27
EP2425823A1 (en) 2012-03-07
BRPI0309544B1 (pt) 2018-04-03
AU2003224041A1 (en) 2003-10-20
US20140296277A1 (en) 2014-10-02
KR20070006945A (ko) 2007-01-11
EP1639997A1 (en) 2006-03-29
HUE032529T2 (en) 2017-09-28
DK200700243U1 (da) 2007-11-09
CA2478523A1 (en) 2003-10-16
DK2425821T3 (da) 2017-08-28
HK1254279A1 (zh) 2019-07-19
JP5932209B2 (ja) 2016-06-08
CN1646102B (zh) 2012-08-15
EP1492505A2 (en) 2005-01-05
IL163990A (en) 2010-04-29
EP2243471A1 (en) 2010-10-27
US20140045878A1 (en) 2014-02-13
WO2003084520A3 (en) 2004-03-11
IL163989A0 (en) 2005-12-18
BR0309004A (pt) 2005-02-01
CA2478515A1 (en) 2003-10-16
ZA200407317B (en) 2005-08-31
TW200403996A (en) 2004-03-16
AR090677A2 (es) 2014-11-26
EP1639996A1 (en) 2006-03-29
SI1492505T1 (sl) 2015-10-30
SI2425824T1 (sl) 2017-06-30
JP2010180233A (ja) 2010-08-19
EP2308474A1 (en) 2011-04-13
RU2006128796A (ru) 2008-02-20
RU2297225C2 (ru) 2007-04-20
EP1492506B2 (en) 2016-06-29
HK1072366A1 (en) 2005-08-26
AU2003224041B2 (en) 2006-07-13
EP2425821B1 (en) 2017-05-10
CN1646102A (zh) 2005-07-27
DE17169621T1 (de) 2019-12-19
US20180214443A1 (en) 2018-08-02
CN107669681A (zh) 2018-02-09
CA2708900C (en) 2019-06-04
SI2425821T1 (sl) 2017-06-30
CY1119120T1 (el) 2018-02-14
IL200621A (en) 2016-02-29
EP2319496A1 (en) 2011-05-11
EP2425821A1 (en) 2012-03-07
AU2003224040B2 (en) 2006-06-22
KR100717591B1 (ko) 2007-05-15
AR039378A1 (es) 2005-02-16
BR0309544A (pt) 2005-02-01
US9907793B2 (en) 2018-03-06
US20170231978A1 (en) 2017-08-17
EP2311438A1 (en) 2011-04-20
PH12018000176A1 (en) 2018-11-19
TNSN04192A1 (fr) 2007-03-12
JP2014129397A (ja) 2014-07-10
KR100784341B1 (ko) 2007-12-13
SI2425825T1 (sl) 2017-05-31
EP2425824A1 (en) 2012-03-07
CY1116640T1 (el) 2017-03-15
DK2425825T3 (da) 2017-02-20
ES2627298T3 (es) 2017-07-27
CO5611100A2 (es) 2006-02-28
WO2003084520A2 (en) 2003-10-16
LT2425821T (lt) 2017-07-25
TWI337077B (en) 2011-02-11
CO5611093A2 (es) 2006-02-28
SI1492506T1 (sl) 2009-04-30
US20170112828A1 (en) 2017-04-27
ES2320748T5 (es) 2017-02-20
EP1492505B1 (en) 2015-06-03
PT1492505E (pt) 2015-10-06
TW200716113A (en) 2007-05-01
PT2425824T (pt) 2017-08-23
US20050245483A1 (en) 2005-11-03
PT1492506E (pt) 2009-03-16
US20150005335A1 (en) 2015-01-01
LT2425825T (lt) 2017-02-27
DE17154462T1 (de) 2019-12-19
US8846091B2 (en) 2014-09-30
EP1492506A2 (en) 2005-01-05
TWI345973B (en) 2011-08-01
EP3326618A1 (en) 2018-05-30
HUE032656T2 (en) 2017-10-30
JP5107954B2 (ja) 2012-12-26
EP2425825B9 (en) 2017-03-01
JP2005529097A (ja) 2005-09-29
DK200700243U3 (da) 2008-01-25
CY1118921T1 (el) 2018-01-10
WO2003084504A3 (en) 2004-03-11
ES2733044T1 (es) 2019-11-27
KR20040098052A (ko) 2004-11-18
TW200408394A (en) 2004-06-01
GEP20074022B (en) 2007-01-10
EP2308475A1 (en) 2011-04-13
HUE027004T2 (en) 2016-08-29
CA2478515C (en) 2010-09-28
JP4620355B2 (ja) 2011-01-26
IL182742A0 (da) 2007-07-24
ES2733051T1 (es) 2019-11-27
HK1246176A1 (zh) 2018-09-07
EP3241548A1 (en) 2017-11-08
ES2627300T3 (es) 2017-07-27
TWI334779B (en) 2010-12-21
EP2425825A1 (en) 2012-03-07
AU2003224040A1 (en) 2003-10-20
RU2295344C2 (ru) 2007-03-20
PT2425821T (pt) 2017-08-23
ATE418967T2 (de) 2009-01-15
EP2316428A1 (en) 2011-05-04
EP2316429A1 (en) 2011-05-04
DE60325567D1 (de) 2009-02-12
IL163990A0 (en) 2005-12-18
MXPA04009714A (es) 2005-12-05
EP1492506B1 (en) 2008-12-31
AP2004003137A0 (en) 2004-09-30
CN1642529A (zh) 2005-07-20
DK2425824T5 (da) 2018-02-12
BRPI0309544B8 (pt) 2021-05-25
GEP20064022B (en) 2007-01-10
DK1492505T3 (da) 2015-08-10
ZA200407267B (en) 2005-08-31
US9555000B2 (en) 2017-01-31
HK1166463A1 (zh) 2012-11-02
JP2009167198A (ja) 2009-07-30
DK2425821T5 (da) 2018-02-12
US20120183612A1 (en) 2012-07-19
ES2320748T3 (es) 2009-05-28
HK1072367A1 (en) 2005-08-26
RU2342935C2 (ru) 2009-01-10
AP2004003138A0 (en) 2004-09-30
DK1492506T4 (da) 2016-10-03
DE20321531U1 (de) 2007-11-22
US20140045877A1 (en) 2014-02-13
CN100411611C (zh) 2008-08-20
JP2005528375A (ja) 2005-09-22
WO2003084504A2 (en) 2003-10-16
CN102813654A (zh) 2012-12-12
AP2397A (en) 2012-04-23
GEP20084485B (en) 2008-09-25
MA27249A1 (fr) 2005-03-01
PT2425825T (pt) 2017-02-13
DE20308436U1 (de) 2003-09-18
EP2425824B1 (en) 2017-05-10
EP2425825B1 (en) 2016-11-16
JP4755810B2 (ja) 2011-08-24
FI7846U1 (fi) 2008-04-28
CY1108914T1 (el) 2014-07-02
US20050245556A1 (en) 2005-11-03
NZ535286A (en) 2007-07-27
ES2608006T3 (es) 2017-04-05
US9655855B2 (en) 2017-05-23
LT2425824T (lt) 2017-07-25
HUE031668T2 (en) 2017-07-28
US8846090B2 (en) 2014-09-30
CA2708900A1 (en) 2003-10-16
MA27116A1 (fr) 2004-12-20
US10420762B2 (en) 2019-09-24
IL200621A0 (en) 2011-07-31
MXPA04009713A (es) 2005-01-11
FIU20070322U0 (fi) 2007-08-17
CY1119168T1 (el) 2018-02-14
KR20040098050A (ko) 2004-11-18
DK1492506T3 (da) 2009-03-16
AR039379A1 (es) 2005-02-16
AP2043A (en) 2009-09-09
RU2004130845A (ru) 2005-06-10

Similar Documents

Publication Publication Date Title
DK2425824T3 (da) Farmaceutisk præparat indeholdende oxycodon og naloxon
US9258035B2 (en) Multi-mode communication ingestible event markers and systems, and methods of using the same
US20220311474A1 (en) System for supply chain management
US10292642B2 (en) Electronic medication compliance monitoring system and associated methods
WO2000033246A1 (en) Method of and system for identifying medical products
US11819337B2 (en) Ingestible electronic medical device
JP2007175263A (ja) 試験薬服用情報収集器